• logo

Unmet Clinical Need

CAR T cell therapies rely upon a multi-step process involving T cell activation and ex vivo expansion over several weeks.  This triggers T cell differentiation (and loss of potency) and requires high labor and material costs. 

Proposed Healthcare Solution

A microfluidic device to optimize CAR T cell generation

Development Stage

Prototype Development

Funding Cycle

2021-2022

Team

Saba Ghassemi, PhD
Roddy O'Connor, PhD

 

For more information on this technology, please contact Penn Center for Innovation at pciinfo@pci.upenn.edu.